Glycoconjugate vaccines for use in immune-compromised populations

Details for Australian Patent Application No. 2002365253 (hide)

Owner Nabi BioPharmaceuticals

Inventors Fattom, Ali I; Naso, Robert B

Agent Freehills

Pub. Number AU-B-2002365253

PCT Number PCT/US02/29601

PCT Pub. Number WO2003/061558

Priority 09/955,585 19.09.01 US

Filing date 19 September 2002

Wipo publication date 2 September 2003

Acceptance publication date 22 February 2007

International Classifications

A61K 39/085 (2006.01) Medicinal preparations containing antigens or antibodies - Staphylococcus

A61P 31/04 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Event Publications

7 August 2003 Complete Application Filed

  Priority application(s): 09/955,585 19.09.01 US

18 September 2003 Application Open to Public Inspection

  Published as AU-B-2002365253

22 February 2007 Application Accepted

  Published as AU-B-2002365253

21 June 2007 Standard Patent Sealed

5 August 2010 Assignment Registered

  Nabi BioPharmaceuticals The patent has been assigned to GLAXOSMITHKLINE BIOLOGICALS SA

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002365254-SUPPORTED NANOPARTICLE CATALYST

2002365252-Improved methods for determining binding affinities